Anticancer properties of zoledronic acid

Jonathan Green, Allan Lipton

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

Zoledronic acid effectively reduces/delays skeletal-related events in patients with metastatic disease or skeletal-related cancers. Emerging data suggest that zoledronic acid may also exhibit anticancer properties. Zoledronic acid ± anticancer therapies in animal models inhibits soft-tissue tumor growth, decreases tumor cell proliferation, increases apoptosis, inhibits angiogenesis, alters tumor-associated macrophage function, and enhances immune surveillance. Data from in vitro and pilot studies suggest that zoledronic acid inhibits tumor cell dissemination in bone marrow, and early clinical data show that it may improve disease-related outcomes. Ongoing studies will further elucidate the role of zoledronic acid in cancer patients.

Original languageEnglish (US)
Pages (from-to)944-957
Number of pages14
JournalCancer Investigation
Volume28
Issue number9
DOIs
StatePublished - Oct 1 2010

Fingerprint

zoledronic acid
Neoplasms
Animal Models
Bone Marrow
Macrophages
Cell Proliferation

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Green, Jonathan ; Lipton, Allan. / Anticancer properties of zoledronic acid. In: Cancer Investigation. 2010 ; Vol. 28, No. 9. pp. 944-957.
@article{f8d59a147f2245609eebc1fb73dc5d1c,
title = "Anticancer properties of zoledronic acid",
abstract = "Zoledronic acid effectively reduces/delays skeletal-related events in patients with metastatic disease or skeletal-related cancers. Emerging data suggest that zoledronic acid may also exhibit anticancer properties. Zoledronic acid ± anticancer therapies in animal models inhibits soft-tissue tumor growth, decreases tumor cell proliferation, increases apoptosis, inhibits angiogenesis, alters tumor-associated macrophage function, and enhances immune surveillance. Data from in vitro and pilot studies suggest that zoledronic acid inhibits tumor cell dissemination in bone marrow, and early clinical data show that it may improve disease-related outcomes. Ongoing studies will further elucidate the role of zoledronic acid in cancer patients.",
author = "Jonathan Green and Allan Lipton",
year = "2010",
month = "10",
day = "1",
doi = "10.3109/07357907.2010.512598",
language = "English (US)",
volume = "28",
pages = "944--957",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "9",

}

Anticancer properties of zoledronic acid. / Green, Jonathan; Lipton, Allan.

In: Cancer Investigation, Vol. 28, No. 9, 01.10.2010, p. 944-957.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Anticancer properties of zoledronic acid

AU - Green, Jonathan

AU - Lipton, Allan

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Zoledronic acid effectively reduces/delays skeletal-related events in patients with metastatic disease or skeletal-related cancers. Emerging data suggest that zoledronic acid may also exhibit anticancer properties. Zoledronic acid ± anticancer therapies in animal models inhibits soft-tissue tumor growth, decreases tumor cell proliferation, increases apoptosis, inhibits angiogenesis, alters tumor-associated macrophage function, and enhances immune surveillance. Data from in vitro and pilot studies suggest that zoledronic acid inhibits tumor cell dissemination in bone marrow, and early clinical data show that it may improve disease-related outcomes. Ongoing studies will further elucidate the role of zoledronic acid in cancer patients.

AB - Zoledronic acid effectively reduces/delays skeletal-related events in patients with metastatic disease or skeletal-related cancers. Emerging data suggest that zoledronic acid may also exhibit anticancer properties. Zoledronic acid ± anticancer therapies in animal models inhibits soft-tissue tumor growth, decreases tumor cell proliferation, increases apoptosis, inhibits angiogenesis, alters tumor-associated macrophage function, and enhances immune surveillance. Data from in vitro and pilot studies suggest that zoledronic acid inhibits tumor cell dissemination in bone marrow, and early clinical data show that it may improve disease-related outcomes. Ongoing studies will further elucidate the role of zoledronic acid in cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=77957977187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957977187&partnerID=8YFLogxK

U2 - 10.3109/07357907.2010.512598

DO - 10.3109/07357907.2010.512598

M3 - Review article

VL - 28

SP - 944

EP - 957

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 9

ER -